AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix Inc. (NASDAQ:SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with an unmet medical need, has selected IBN, a multifaceted financial news and publishing company serving private and public entities, to spearhead its corporate communications efforts. Soligenix operates through two key segments: its Specialized BioTherapeutics division, which focuses on oncology and infla ...